No one has really talked much about Paul Field, PharmAust Business Development Advisor.
The caption below is from the PharmAust website.
Paul's role is to assist PharmAust with it's partnering campaign for Monepantel.
An incredible comment really - we have hired Paul, with a wealth of experience, to assist with finding partners. Paul has been with us since April.
I notice Paul was on the investment committee for the Horizon 3 Healthcare fund which deployed $80M ... including getting in early on Neuren Pharmaceuticals.
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-739
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $97.22M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.0¢ | 19.5¢ | $199.9K | 1.004M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 457971 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 1207 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |